Tag Archives: BAP1

Mesothelioma and Metastatic Cancer: New Test Can Reliably Tell the Difference

mesothelioma and metastatic cancer

Italian scientists have come up with what they believe is a nearly foolproof way to tell the difference between mesothelioma and metastatic cancer.  Malignant mesothelioma is a membrane cancer caused by asbestos exposure. Metastatic cancer can start anywhere in the body. It can cause tumors on the pleural membrane that may be mistaken for mesothelioma.  It is important for doctors to distinguish between these two types of malignancies. Mesothelioma and metastatic cancer are often treated differently. The Italian researchers say two biomarkers may make it easier to know which is which.  The Difference Between Mesothelioma and Metastatic Cancer Metastatic cancer or metastatic carcinoma is cancer that has spread to another part of the body from where it started. This usually … Continue reading Mesothelioma and Metastatic Cancer: New Test Can Reliably Tell the Difference »

Gene Targeting Slows Aggressive Form of Pleural Mesothelioma

Aggressive Form of Pleural Mesothelioma

Scientists in Vienna are developing a new treatment for a particularly aggressive form of pleural mesothelioma.  This form of mesothelioma occurs in people with a genetic mutation. The mutation produces signals that fuel tumor growth. These patients typically have an even worse prognosis than other mesothelioma patients.  But the Austrian team came up with a way to block activation of the mutated gene. If the gene does not send its signal, this aggressive form of pleural mesothelioma may grow more slowly.  Aggression Fueled by Telomerase Malignant mesothelioma is one of the most aggressive kinds of cancer. It starts on the membranes around organs and can quickly spread to other parts of the body. By the time most people notice symptoms, … Continue reading Gene Targeting Slows Aggressive Form of Pleural Mesothelioma »

BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis

BAP1 Expression and Mesothelioma Prognosis

A new report says the prognostic role of BAP1 expression in mesothelioma is not as cut-and-dried as some studies suggest. Italian researchers analyzed the cases of 698 patients with pleural mesothelioma. The group included 60 of their own patients and another 638 from other studies. Their analysis suggests that mesothelioma prognosis has more to do with subtype than with genetic BAP1 expression. They caution doctors not to put too much stock in a patient’s BAP1 status without also considering other factors. Genetic Alterations and Mesothelioma Survival Asbestos exposure is the primary cause of mesothelioma. But not everyone who is exposed to asbestos gets cancer. This may have to do with their genetic makeup. Certain genetic alterations may make a person … Continue reading BAP1 Expression Not an Independent Factor in Mesothelioma Prognosis »

Promising Data on New Mesothelioma Pill Presented at National Conference

new mesothelioma pill

Doctors researching a new mesothelioma pill presented research on the drug at a national virtual conference in May.  The ASCO conference is one of the most important gatherings of cancer doctors in the country. This year’s online meeting gave them a chance to safely learn about new cancer research. Only the most notable research is presented at the conference. The new mesothelioma pill made the cut because research suggests it can help patients with asbestos cancer live longer.  How the New Medication Works Cambridge, Massachusetts-based Epizyme makes the new mesothelioma pill, called tazemetostat (Tazverik). The oral drug blocks the protein EZH2. This protein inhibits the genes that are supposed to suppress tumor growth. Over-expression of EZH2 has been linked to … Continue reading Promising Data on New Mesothelioma Pill Presented at National Conference »

Recommendations for People with a Genetic Predisposition for Mesothelioma

genetic predisposition for mesothelioma

Cancer expects from Ohio State University have just released an updated version of their recommendations for people with a genetic predisposition for mesothelioma.  These people have an inherited mutation on their BAP1 tumor suppressor gene. This mutation puts them at risk for several different types of cancer, including malignant mesothelioma.  It is not possible to prevent cancer in people with this genetic risk factor. But the Ohio State doctors say awareness and screening may help extend the lives of people with a genetic predisposition for mesothelioma.  BAP1 Tumor Predisposition Syndrome BAP1 stands for BRCA association protein 1. The BAP1 gene encodes for the BAP1 protein. BAP1 is one of the proteins that helps keep normal cells from turning into cancer … Continue reading Recommendations for People with a Genetic Predisposition for Mesothelioma »

Possible New Drug for Mesothelioma Gets First FDA Approval

new drug for mesothelioma

A possible new drug for mesothelioma has received FDA approval for the treatment of advanced epithelioid sarcoma.  Tazemetostat (Tazverik) is an oral medication made by a company called Epizyme. It is a brand new kind of drug that blocks a protein called EZH2. Tazemetostat is in testing for several different types of cancer, including malignant mesothelioma.  The recent FDA approval is an encouraging sign that it could one day be a new drug for mesothelioma.  In Search of a New Drug for Mesothelioma  Malignant mesothelioma is one of the most serious consequences of exposure to asbestos. Once asbestos fibers get into the lungs and other tissues, they never leave. Their presence sets up a cascade of cellular reactions that can … Continue reading Possible New Drug for Mesothelioma Gets First FDA Approval »

Spotting the BAP1 Gene Mutation in Mesothelioma Patients

BAP1 gene mutation

New guidelines may make it easier to tell which mesothelioma patients contracted the disease because of a BAP1 gene mutation. The knowledge could have an impact on mesothelioma treatment planning. BAP1 stands for BRCA associated protein-1. People who have an inherited BAP1 gene mutation face a higher risk for several conditions, including malignant mesothelioma.  Very few mesothelioma patients have the mutation and gene testing is not routine. So researchers at a top US cancer center have developed a set of screening criteria. The criteria may help predict which mesothelioma patients could benefit from genetic testing. Testing for the Altered Gene Mesothelioma is just one of the conditions associated with the inherited BAP1 gene mutation. People with this condition are also … Continue reading Spotting the BAP1 Gene Mutation in Mesothelioma Patients »

BAP1 Can Distinguish Mesothelioma from Other Conditions

Scientist looking at mesothelioma cells

German scientists say a protein could help doctors distinguish mesothelioma from other conditions. Malignant mesothelioma is a cancer that grows on the membranes around organs. These membranes are called mesothelial membranes. But other conditions can also grow on mesothelial membranes. One of those conditions is adenomatoid tumors. Adenomatoid tumors are benign but, even under the microscope, their cells can look a lot like malignant mesothelioma. Now, a group of pathologists in Germany say the BAP1 protein can tell these two conditions apart. If doctors can distinguish mesothelioma from other conditions early enough, mesothelioma patients may have better outcomes. BAP1 Loss and Mesothelioma BAP1 is a protein encoded by the BAP1 gene. BAP1 is one of the proteins that helps keep … Continue reading BAP1 Can Distinguish Mesothelioma from Other Conditions »

Genetic Mutation Improves Mesothelioma Survival Odds

Another new study has been released that supports the idea that mesothelioma patients who are missing the tumor suppressor called BAP1 are more likely to survive longer than those who have intact BAP1 genes. The BRCA-1-associated protein 1 (BAP1) gene is located on the chromosome 3p21. Because the job of BAP1 is to help suppress cancer, a mutation that causes this gene to be inactive raises the risk that a person could get mesothelioma or another cancer. BAP1 loss has also been associated with increased risk of skin cancer, renal cell cancer and some lung and breast cancers. But there appears to be an upside to BAP1 loss. Data published in the journal Pathology suggests that mesothelioma patients with BAP1 … Continue reading Genetic Mutation Improves Mesothelioma Survival Odds »

BAP1 Mutation Unlikely to Trigger Sporadic Mesothelioma

But researchers at the Clinic of Oncology at the University Hospital of Zurich and University Hospitals in Leuven, Belgium say they have evidence to show that BAP1 mutations account for only a tiny percentage of sporadic mesothelioma cases. Mesothelioma is normally associated with exposure to asbestos dust and previous studies have found that people with the BAP1 mutation are more susceptible to cancer-causing effects of asbestos. Twenty-three percent of mesothelioma tumor specimens have been found to have a mutated BAP1 gene. But some cases of mesothelioma appear to arise “sporadically”, with no history of asbestos exposure.  Researchers around the world have long been trying to pinpoint the reasons these sporadic mesothelioma cases develop in an effort to prevent and/or treat … Continue reading BAP1 Mutation Unlikely to Trigger Sporadic Mesothelioma »